Edgewise Therapeutics, Inc. — Operating Income by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/08d1abad-bdf8-4fff-8017-ac0145a3d0f2/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-191.4M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-020112 |
| FY 2024 | $-158.8M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-002006 |
| FY 2023 | $-114.4M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-001467 |
| FY 2022 | $-71.7M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-001895 |
| FY 2021 | $-43.2M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-001850 |
| FY 2020 | $-17.2M | 2020-01-01 – 2020-12-31 | evidence 0001558370-22-001850 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).